Guro Kristine Kleivi Sahlberg

• Torland, Lilly Anne; Lai, Xiaoran; Kumar, Surendra; Riis, Margit; Geisler, Jürgen & Lüders, Torben [Vis alle 10 forfattere av denne artikkelen] (2024). Benign breast tumors may arise on different immunological backgrounds. Molecular Oncology. ISSN 1574-7891. doi: 10.1002/1878-0261.13655.
• Skjerven, Helle; Myklebust, Even Moa; Korvald, Christian; Stubberud, Kjetil; Hovda, Tone & Porojnicu, Alina Carmen [Vis alle 10 forfattere av denne artikkelen] (2023). Long-term follow-up of complex oncoplastic breast-conserving surgery, standard breast conservation and skin-sparing mastectomy in DCIS - a register-based study. European Journal of Surgical Oncology. ISSN 0748-7983. 50(2). doi: 10.1016/j.ejso.2023.107938.
• Morra, Anna; Schreurs, Maartje A. C.; Andrulis, Irene L.; Anton-Culver, Hoda; Augustinsson, Annelie & Beckmann, Matthias W. [Vis alle 125 forfattere av denne artikkelen] (2023). Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. Cancer Medicine. ISSN 2045-7634. 12(15), s. 16142–16162. doi: 10.1002/cam4.6272. Fulltekst i vitenarkiv
• Levi, Hagai; Carmi, Shai; Rosset, Saharon; Yerushalmi, Rinat; Zick, Aviad & Yablonski-Peretz, Tamar [Vis alle 155 forfattere av denne artikkelen] (2023). Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. Journal of Medical Genetics. ISSN 0022-2593. 60(12), s. 1186–1197. doi: 10.1136/jmg-2023-109185. Fulltekst i vitenarkiv
• Figlioli, Gisella; Billaud, Amandine; Wang, Qin; Bolla, Manjeet K.; Dennis, Joe & Lush, Michael [Vis alle 96 forfattere av denne artikkelen] (2023). Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases. Cancers. ISSN 2072-6694. 15(13). doi: 10.3390/cancers15133313. Fulltekst i vitenarkiv
• Figlioli, Gisella; Billaud, Amandine; Ahearn, Thomas U.; Antonenkova, Natalia N.; Becher, Heiko & Beckmann, Matthias W. [Vis alle 114 forfattere av denne artikkelen] (2023). FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women. European Journal of Human Genetics. ISSN 1018-4813. 31(5), s. 578–587. doi: 10.1038/s41431-022-01257-w. Fulltekst i vitenarkiv Vis sammendrag

  Evidence from literature, including the BRIDGES study, indicates that germline protein truncating variants (PTVs) in FANCM confer moderately increased risk of ER-negative and triple-negative breast cancer (TNBC), especially for women with a family history of the disease. Association between FANCM missense variants (MVs) and breast cancer risk has been postulated. In this study, we further used the BRIDGES study to test 689 FANCM MVs for association with breast cancer risk, overall and in ER-negative and TNBC subtypes, in 39,885 cases (7566 selected for family history) and 35,271 controls of European ancestry. Sixteen common MVs were tested individually; the remaining rare 673 MVs were tested by burden analyses considering their position and pathogenicity score. We also conducted a meta-analysis of our results and those from published studies. We did not find evidence for association for any of the 16 variants individually tested. The rare MVs were significantly associated with increased risk of ER-negative breast cancer by burden analysis comparing familial cases to controls (OR = 1.48; 95% CI 1.07–2.04; P = 0.017). Higher ORs were found for the subgroup of MVs located in functional domains or predicted to be pathogenic. The meta-analysis indicated that FANCM MVs overall are associated with breast cancer risk (OR = 1.22; 95% CI 1.08–1.38; P = 0.002). Our results support the definition from previous analyses of FANCM as a moderate-risk breast cancer gene and provide evidence that FANCM MVs could be low/moderate risk factors for ER-negative and TNBC subtypes. Further genetic and functional analyses are necessary to clarify better the increased risks due to FANCM MVs

• Hovda, Tone; Larsen, Marthe; Romundstad, Linda; Sahlberg, Guro Kristine Kleivi & Hofvind, Solveig Sand-Hanssen (2023). Breast cancer missed at screening; hindsight or mistakes? European Journal of Radiology. ISSN 0720-048X. 165. doi: 10.1016/j.ejrad.2023.110913. Fulltekst i vitenarkiv
• Morra, Anna; Mavaddat, Nasim; Muranen, Taru A.; Ahearn, Thomas U.; Allen, Jamie & Andrulis, Irene L. [Vis alle 84 forfattere av denne artikkelen] (2023). The impact of coding germline variants on contralateral breast cancer risk and survival. American Journal of Human Genetics. ISSN 0002-9297. 110(3), s. 475–486. doi: 10.1016/j.ajhg.2023.02.003. Fulltekst i vitenarkiv
• Svartdal, Lisa Gregusson; Haugen, Mads; Hongisto, Vesa; Aure, Miriam Ragle; Leivonen, Suvi-Katri & Kristensen, Vessela N. [Vis alle 10 forfattere av denne artikkelen] (2023). High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PLOS ONE. ISSN 1932-6203. 18(1). doi: 10.1371/journal.pone.0280507. Fulltekst i vitenarkiv
• Mueller, Stefanie H.; Lai, Alvina G.; Valkovskaya, Maria; Michailidou, Kyriaki; Bolla, Manjeet K. & Wang, Qin [Vis alle 207 forfattere av denne artikkelen] (2023). Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Medicine. ISSN 1756-994X. 15(7). doi: 10.1186/s13073-022-01152-5. Fulltekst i vitenarkiv
• Skjerven, Helle; Myklebust, Even Moa; Korvald, Christian; Porojnicu, Alina Carmen; Kåresen, Rolf & Hofvind, Solveig Sand-Hanssen [Vis alle 8 forfattere av denne artikkelen] (2022). Oncological outcomes after simple and skin-sparing mastectomy of ductal carcinoma in situ: A register-based cohort study of 576 Norwegian women. European Journal of Surgical Oncology. ISSN 0748-7983. doi: 10.1016/j.ejso.2022.11.594.
• Dixon-Suen, Suzanne C.; Lewis, Sarah; Martin, Richard M.; English, Dallas R.; Boyle, Terry & Giles, Graham G. [Vis alle 174 forfattere av denne artikkelen] (2022). Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. British Journal of Sports Medicine. ISSN 0306-3674. 56(20), s. 1157–1170. doi: 10.1136/bjsports-2021-105132. Vis sammendrag

  Objectives Physical inactivity and sedentary behaviour are associated with higher breast cancer risk in observational studies, but ascribing causality is difficult. Mendelian randomisation (MR) assesses causality by simulating randomised trial groups using genotype. We assessed whether lifelong physical activity or sedentary time, assessed using genotype, may be causally associated with breast cancer risk overall, pre/post-menopause, and by case-groups defined by tumour characteristics. Methods We performed two-sample inverse-variance-weighted MR using individual-level Breast Cancer Association Consortium case-control data from 130 957 European-ancestry women (69 838 invasive cases), and published UK Biobank data (n=91 105–377 234). Genetic instruments were single nucleotide polymorphisms (SNPs) associated in UK Biobank with wrist-worn accelerometer-measured overall physical activity (nsnps=5) or sedentary time (nsnps=6), or accelerometer-measured (nsnps=1) or self-reported (nsnps=5) vigorous physical activity. Results Greater genetically-predicted overall activity was associated with lower breast cancer overall risk (OR=0.59; 95% confidence interval (CI) 0.42 to 0.83 per-standard deviation (SD;~8 milligravities acceleration)) and for most case-groups. Genetically-predicted vigorous activity was associated with lower risk of pre/perimenopausal breast cancer (OR=0.62; 95% CI 0.45 to 0.87,≥3 vs. 0 self-reported days/week), with consistent estimates for most case-groups. Greater genetically-predicted sedentary time was associated with higher hormone-receptor-negative tumour risk (OR=1.77; 95% CI 1.07 to 2.92 per-SD (~7% time spent sedentary)), with elevated estimates for most case-groups. Results were robust to sensitivity analyses examining pleiotropy (including weighted-median-MR, MR-Egger). Conclusion Our study provides strong evidence that greater overall physical activity, greater vigorous activity, and lower sedentary time are likely to reduce breast cancer risk. More widespread adoption of active lifestyles may reduce the burden from the most common cancer in women.

• Dorling, Leila; Carvalho, Sara; Allen, Jamie; Parsons, Michael T.; Fortuno, Cristina & Kristensen, Vessela N. [Vis alle 50 forfattere av denne artikkelen] (2022). Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine. ISSN 1756-994X. 14(1), s. 1–17. doi: 10.1186/s13073-022-01052-8. Fulltekst i vitenarkiv Vis sammendrag

  Background: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk, but risks associated with missense variants in these genes are uncertain. Methods: We analyzed data on 59,639 breast cancer cases and 53,165 controls from studies participating in the Breast Cancer Association Consortium BRIDGES project. We sampled training (80%) and validation (20%) sets to ana‑ lyze rare missense variants in ATM (1146 training variants), BRCA1 (644), BRCA2 (1425), CHEK2 (325), and PALB2 (472). We evaluated breast cancer risks according to fve in silico prediction-of-deleteriousness algorithms, functional protein domain, and frequency, using logistic regression models and also mixture models in which a subset of variants was assumed to be risk-associated. Results: The most predictive in silico algorithms were Helix (BRCA1, BRCA2 and CHEK2) and CADD (ATM). Increased risks appeared restricted to functional protein domains for ATM (FAT and PIK domains) and BRCA1 (RING and BRCT domains). For ATM, BRCA1, and BRCA2, data were compatible with small subsets (approximately 7%, 2%, and 0.6%, respectively) of rare missense variants giving similar risk to those of protein truncating variants in the same gene. For CHEK2, data were more consistent with a large fraction (approximately 60%) of rare missense variants giving a lower risk (OR 1.75, 95% CI (1.47–2.08)) than CHEK2 protein truncating variants. There was little evidence for an association with risk for missense variants in PALB2. The best ftting models were well calibrated in the validation set. Conclusions: These results will inform risk prediction models and the selection of candidate variants for functional assays and could contribute to the clinical reporting of gene panel testing for breast cancer susceptibility

• Bjørklund, Sunniva; Aure, Miriam Ragle; Häkkinen, Jari; Vallon-Christersson, Johan; Kumar, Surendra & Bull Evensen, Katrine [Vis alle 34 forfattere av denne artikkelen] (2022). Subtype and cell type specific expression of lncRNAs provide insight into breast cancer. Communications Biology. ISSN 2399-3642. 5(1), s. 1–14. doi: 10.1038/s42003-022-03559-7. Fulltekst i vitenarkiv
• Normann, Lisa Svartdal; Haugen, Mads Haugland; Aure, Miriam Ragle; Kristensen, Vessela N.; Mælandsmo, Gunhild Mari & Sahlberg, Kristine Kleivi (2022). miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy. Breast Cancer: Targets and Therapy. ISSN 1179-1314. 14, s. 25–39. doi: 10.2147/BCTT.S338404. Fulltekst i vitenarkiv Vis sammendrag

  Purpose: Human epidermal growth factor receptor 2 positive (HER2+) breast cancers responding poorly to targeted therapy need improved treatment options. miR-101-5p has shown tumor-suppressive properties in multiple cancer forms, and we assessed the effect and mechanism of action of this miRNA in HER2+ breast cancer. Methods: Expression levels of miR-101-5p in two clinical datasets, TCGA and METABRIC, were compared between tumor and normal adjacent samples, and across molecular subtypes and HER2 status. The ability of miR-101-5p to sensitize for treatment with lapatinib, tucatinib and trastuzumab was explored in HER2+ breast cancer cells responding poorly to such targeted drugs. Proliferation and apoptosis assays and downstream protein analysis were performed. Results: Expression levels of miR-101-5p were significantly lower in tumor compared to normal adjacent tissue (p < 0.001), and particularly low in HER2+ tumors, both the HER2-enriched subtype (p ≤ 0.037) and clinical HER2-status (p < 0.001). In a HER2+ cell line (KPL4) responding poorly to targeted drugs, miR-101-5p overexpression inhibited proliferation (p < 0.001), and combinatorial treatment with lapatinib and trastuzumab significantly further decreased this inhibition (p = 0.004). Proteomic data and in silico analyses revealed PI3K/Akt- and HER2-pathways among the predicted regulated pathways. miR-101-5p alone (p = 0.018) and in combination with lapatinib and trastuzumab (p < 0.001) induced apoptosis, while the targeted drugs alone did not exert any significant effect neither on proliferation nor apoptosis. Conclusion: miR-101-5p acts as a tumor suppressor by inducing apoptosis in HER2+ breast cancer and sensitizes cells with initially poor response to lapatinib and trastuzumab.

• Dennis, Joe; Tyrer, Jonathan P.; Walker, Logan C.; Michailidou, Kyriaki; Dorling, Leila & Kristensen, Vessela N. [Vis alle 50 forfattere av denne artikkelen] (2022). Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology. ISSN 2399-3642. 5, s. 1–15. doi: 10.1038/s42003-021-02990-6. Fulltekst i vitenarkiv Vis sammendrag

  Germline copy number variants (CNVs) are pervasive in the human genome but potential disease associations with rare CNVs have not been comprehensively assessed in large datasets. We analysed rare CNVs in genes and non-coding regions for 86,788 breast cancer cases and 76,122 controls of European ancestry with genome-wide array data. Gene burden tests detected the strongest association for deletions in BRCA1 (P = 3.7E−18). Nine other genes were associated with a p-value < 0.01 including known susceptibility genes CHEK2 (P = 0.0008), ATM (P = 0.002) and BRCA2 (P = 0.008). Outside the known genes we detected associations with p-values < 0.001 for either overall or subtype-specific breast cancer at nine deletion regions and four duplication regions. Three of the deletion regions were in established common susceptibility loci. To the best of our knowledge, this is the first genome-wide analysis of rare CNVs in a large breast cancer case-control dataset. We detected associations with exonic deletions in established breast cancer susceptibility genes. We also detected suggestive associations with non-coding CNVs in known and novel loci with large effects sizes. Larger sample sizes will be required to reach robust levels of statistical significance.

• Ahearn, Thomas U.; Zhang, Haoyu; Michailidou, Kyriaki; Milne, Roger L.; Bolla, Manjeet K. & Dennis, Joe [Vis alle 205 forfattere av denne artikkelen] (2022). Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research. ISSN 1465-5411. 24(1), s. 1–13. doi: 10.1186/s13058-021-01484-x. Fulltekst i vitenarkiv
• Wolowczyk, Camilla; Neckmann, Ulrike; Aure, Miriam Ragle; Hall, Martina; Johannessen, Bjarne & Zhao, Sen [Vis alle 14 forfattere av denne artikkelen] (2022). NRF2 drives an oxidative stress response predictive of breast cancer. Free Radical Biology & Medicine. ISSN 0891-5849. 184, s. 170–184. doi: 10.1016/j.freeradbiomed.2022.03.029. Fulltekst i vitenarkiv
• Skjerven, Helle; Danielsen, Anders Skyrud; Schlichting, Ellen; Sahlberg, Kristine Kleivi & Hofvind, Solveig Sand-Hanssen (2022). Treatment of Ductal Carcinoma in situ: A Register-Based Study of Norwegian Women Diagnosed between 1995 and 2018. Breast Care. ISSN 1661-3791. 17(5), s. 486–494. doi: 10.1159/000524564. Fulltekst i vitenarkiv Vis sammendrag

  The incidence of ductal carcinoma in situ (DCIS) has increased after implementation of mammographic screening. The lesion represents management challenges due to its undetermined growth pattern. We aimed to explore treatment of women aged 48–71 years diagnosed with DCIS between 1995 and 2018, by detection mode and histopathological characteristics. Material and Methods: Data on surgical treatment and radiation therapy (RT) of 4,995 women diagnosed with DCIS were retrieved from the Cancer Registry of Norway. We described the percentage and frequency of breast-conserving treatment (BCT) for participants in BreastScreen Norway (screen-detected) and nonparticipants. We estimated the relative risk (RR) of BCT, using log-binomial regression models. Results: Use of BCT increased from about 40% in 1995 to 85% in 2018. Use of BCT was more common among older than younger women and more commonly used for screen-detected versus tumors detected outside the screening program. Nine out of ten women with tumors ≤10 mm were treated with BCT and two out of ten with tumors >50 mm. RT was given to 89.3% of the women with tumors ≤10 mm, 34.1% of those with tumors classified as van Nuys’ grade 1 and <10 mm and 96.0% of the tumors >50 mm. Use of BCT was less common for tumors >50 mm compared to <10 mm (RR adjusted for age, detection mode, van Nuys’ grade, and localization: 0.26, 95% CI: 0.19–0.36). Conclusion: BCT was increasingly used among women diagnosed with DCIS in Norway during the period from 1995 to 2018, particularly for screen-detected, small lesions with low van Nuys’ grade.

• Park, Hanla A.; Neumeyer, Sonja; Michailidou, Kyriaki; Bolla, Manjeet K.; Wang, Qin & Kristensen, Vessela N. [Vis alle 50 forfattere av denne artikkelen] (2021). Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer. ISSN 0007-0920. 125(8), s. 1135–1145. doi: 10.1038/s41416-021-01432-8. Fulltekst i vitenarkiv
• Johnson, Nichola; Maguire, Sarah; Morra, Anna; Kapoor, Pooja Middha; Tomczyk, Katarzyna & Kristensen, Vessela N. [Vis alle 50 forfattere av denne artikkelen] (2021). CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer. ISSN 0007-0920. 124, s. 842–854. doi: 10.1038/s41416-020-01185-w. Fulltekst i vitenarkiv
• Rye, Inga Hansine; Huse, Kanutte; Josefsson, Sarah Elisabet; Kildal, Wanja; Danielsen, Håvard Emil Greger & Schlichting, Ellen [Vis alle 28 forfattere av denne artikkelen] (2021). Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression. Molecular Oncology. ISSN 1574-7891. 16(1), s. 88–103. doi: 10.1002/1878-0261.13047. Fulltekst i vitenarkiv
• Morra, Anna; Escala-Garcia, Maria; Beesley, Jonathan; Keeman, Renske; Canisius, Sander & Ahearn, Thomas U. [Vis alle 50 forfattere av denne artikkelen] (2021). Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research. ISSN 1465-5411. 23:86(1), s. 1–18. doi: 10.1186/s13058-021-01450-7. Fulltekst i vitenarkiv
• Park, JooYong; Choi, Ji-Yeob; Choi, Jaesung; Chung, Seokang; Song, Nan & Park, Sue K [Vis alle 50 forfattere av denne artikkelen] (2021). Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies? Cancers. ISSN 2072-6694. 13:2370(10), s. 1–21. doi: 10.3390/cancers13102370. Fulltekst i vitenarkiv
• Hovda, Tone; Hoff, Solveig Roth; Larsen, Marthe; Romundstad, Linda; Sahlberg, Kristine Kleivi & Hofvind, Solveig (2021). True and Missed Interval Cancer in Organized Mammographic Screening: A Retrospective Review Study of Diagnostic and Prior Screening Mammograms. Academic Radiology. ISSN 1076-6332. 29, s. S180–S191. doi: 10.1016/j.acra.2021.03.022. Fulltekst i vitenarkiv Vis sammendrag

  Rationale and Objectives To explore radiological aspects of interval breast cancer in a population-based screening program. Materials and Methods We performed a consensus-based informed review of mammograms from diagnosis and prior screening from women diagnosed with interval cancer 2004-2016 in BreastScreen Norway. Cases were classified as true (no findings on prior screening mammograms), occult (no findings at screening or diagnosis), minimal signs (minor/non-specific findings) and missed (obvious findings). We analyzed mammographic findings, density, time since prior screening, and histopathological characteristics between the classification groups. Results The study included 1010 interval cancer cases. Mean age at diagnosis was 61 years (SD = 6), mean time between screening and diagnosis 14 months (SD = 7). A total of 48% (479/1010) were classified as true or occult, 28% (285/1010) as minimal signs and 24% (246/1010) as missed. We observed no differences in mammographic density between the groups, except from a higher percentage of dense breasts in women with occult cancer. Among cancers classified as missed, about 1/3 were masses and 1/3 asymmetries at prior screening. True interval cancers were diagnosed later in the screening interval than the other classification categories. No differences in histopathological characteristics were observed between true, minimal signs and missed cases. Conclusion In an informed review, 24% of the interval cancers were classified as missed based on visibility and mammographic findings on prior screening mammograms. Three out of four true interval cancers were diagnosed in the second year of the screening interval. We observed no statistical differences in histopathological characteristics between true and missed interval cancers.

• Ben-Elazar, Shay; Aure, Miriam Ragle; Jonsdottir, Kristin; Leivonen, Suvi-Katri; Kristensen, Vessela N. & Janssen, Emiel [Vis alle 9 forfattere av denne artikkelen] (2021). miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer. PLoS Computational Biology. ISSN 1553-734X. 17(2). doi: 10.1371/JOURNAL.PCBI.1008608. Fulltekst i vitenarkiv
• Aure, Miriam Ragle; Fleischer, Thomas; Bjørklund, Sunniva; Ankill, Jørgen; Castro Mondragón, Jaime Abraham & Børresen-Dale, Anne-Lise [Vis alle 11 forfattere av denne artikkelen] (2021). Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer. Genome Medicine. ISSN 1756-994X. 13:72, s. 1–21. doi: 10.1186/s13073-021-00880-4. Fulltekst i vitenarkiv
• Svartdal Normann, Lisa Gregusson; Aure, Miriam Ragle; Leivonen, Suvi-Katri; Haugen, Mads Haugland; Hongisto, Vesa & Kristensen, Vessela N. [Vis alle 8 forfattere av denne artikkelen] (2021). MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro. Scientific Reports. ISSN 2045-2322. 11:10893, s. 1–11. doi: 10.1038/s41598-021-90385-2. Fulltekst i vitenarkiv
• Liu, Jingjing; van der Smissen, Wendy J. C. Prager; Collee, Margriet J.; Bolla, Manjeet K.; Wang, Qin & Kristensen, Vessela N. [Vis alle 82 forfattere av denne artikkelen] (2020). Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports. ISSN 2045-2322. 10:9688(1), s. 1–14. doi: 10.1038/s41598-020-65665-y. Fulltekst i vitenarkiv Vis sammendrag

  In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. Since HOXB13 p.G84E is a prostate cancer risk allele, we evaluated the association between HOXB13 germline mutations and breast cancer risk in a previous study consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherlands. Although both recurrent HOXB13 mutations p.G84E and p.R217C were not associated with breast cancer risk, the risk estimation for p.R217C was not very precise. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR=1.035, 95% CI=0.859–1.246, P=0.718 and OR=0.798, 95% CI=0.482–1.322, P=0.381 respectively), nor in specifc high-risk subgroups or breast cancer subtypes. Thus, although involved in breast cancer progression, HOXB13 is not a material breast cancer susceptibility gene.

• Kramer, Iris; Hooning, Maartje J.; Mavaddat, Nasim; Hauptmann, Michael; Keeman, Renske & Steyerberg, Ewout W. [Vis alle 54 forfattere av denne artikkelen] (2020). Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics. ISSN 0002-9297. 107(5), s. 837–848. doi: 10.1016/j.ajhg.2020.09.001. Vis sammendrag

  Previous research has shown that polygenic risk scores (PRSs) can be used to stratify women according to their risk of developing primary invasive breast cancer. This study aimed to evaluate the association between a recently validated PRS of 313 germline variants (PRS313) and contralateral breast cancer (CBC) risk. We included 56,068 women of European ancestry diagnosed with first invasive breast cancer from 1990 onward with follow-up from the Breast Cancer Association Consortium. Metachronous CBC risk (N = 1,027) according to the distribution of PRS313 was quantified using Cox regression analyses. We assessed PRS313 interaction with age at first diagnosis, family history, morphology, ER status, PR status, and HER2 status, and (neo)adjuvant therapy. In studies of Asian women, with limited follow-up, CBC risk associated with PRS313 was assessed using logistic regression for 340 women with CBC compared with 12,133 women with unilateral breast cancer. Higher PRS313 was associated with increased CBC risk: hazard ratio per standard deviation (SD) = 1.25 (95%CI = 1.18–1.33) for Europeans, and an OR per SD = 1.15 (95%CI = 1.02–1.29) for Asians. The absolute lifetime risks of CBC, accounting for death as competing risk, were 12.4% for European women at the 10th percentile and 20.5% at the 90th percentile of PRS313. We found no evidence of confounding by or interaction with individual characteristics, characteristics of the primary tumor, or treatment. The C-index for the PRS313 alone was 0.563 (95%CI = 0.547–0.586). In conclusion, PRS313 is an independent factor associated with CBC risk and can be incorporated into CBC risk prediction models to help improve stratification and optimize surveillance and treatment strategies.

• Skjerven, Helle; Danielsen, Anders Skyrud; Schlichting, Ellen; Sahlberg, Kristine Kleivi & Hofvind, Solveig (2020). Kirurgisk behandling av brystkreft i Norge 2003–18. Tidsskrift for Den norske legeforening. ISSN 0029-2001. doi: 10.4045/tidsskr.20.0090. Vis sammendrag

  BAKGRUNN Brystbevarende kirurgi er anbefalt i Norge og internasjonalt ved brystkreft påvist i et tidlig stadium. Vi har analysert operasjonsmetode for brystkreftpasienter etter behandlende sykehus, alder ved diagnose, deteksjonsmetode og svulstenes histopatologiske karakteristikk for perioden fra 2003 til 2018. MATERIALE OG METODE Informasjon om kvinner i alle aldre diagnostisert med infiltrerende brystkreft (n = 47 004) ble hentet fra Kreftregisterets databaser. Vi ekskluderte kvinner med fjernmetastaser ved diagnose (n = 1 773) og de uten registrert operasjonsmetode (n = 2 638). Deteksjonsmetode ble definert som screeningoppdaget brystkreft, intervallkreft eller brystkreft påvist utenfor Mammografiprogrammet. Valg av operasjonsmetode ble sammenlignet ved deskriptive analyser. RESULTATER Noe over halvparten (23 661 av 42 593, dvs. 55,6 %) av kvinnene som fikk påvist brystkreft i studieperioden, ble operert med brystbevarende kirurgi. Andelen økte fra 1 189/2 423 (49,1 %) i 2003 til 2 070/2 958 (70,0 %) i 2018. Det var store forskjeller mellom sykehusene. I perioden 2015–18 fant vi den høyeste andelen brystbevarende kirurgi, 175/187 (93,6 %), ved screeningoppdaget brystkreft operert på Ålesund sjukehus, mens vi fant den laveste andelen, 121/351 (34,5 %), blant kvinner med brystkreft påvist utenfor Mammografiprogrammet, operert på Radiumhospitalet. Brystbevarende kirurgi ble oftest benyttet hos kvinner med små svulster uten spredning til lymfeknuter i armhulen. FORTOLKNING Vi fant betydelige forskjeller i operasjonsmetode for brystkreft mellom sykehusene og mellom ulike deteksjonsmetodene.

• Tinholt, Mari; Stavik, Benedicte; Tekpli, Xavier; Garred, Øystein; Borgen, Elin & Kristensen, Vessela N. [Vis alle 9 forfattere av denne artikkelen] (2020). Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer. Oncoimmunology. ISSN 2162-4011. 9:e1824644(1), s. 1–12. doi: 10.1080/2162402X.2020.1824644. Fulltekst i vitenarkiv
• Hovda, Tone; Tsuruda, Kaitlyn; Hoff, Solveig Roth; Sahlberg, Kristine Kleivi & Hofvind, Solveig (2020). Radiological review of prior screening mammograms of screen-detected breast cancer. European Radiology. ISSN 0938-7994. 31(4), s. 2568–2579. doi: 10.1007/s00330-020-07130-y. Fulltekst i vitenarkiv Vis sammendrag

  Objective: To perform a radiological review of mammograms from prior screening and diagnosis of screen-detected breast cancer in BreastScreen Norway, a population-based screening program. Methods: We performed a consensus-based informed review of mammograms from prior screening and diagnosis for screen-detected breast cancers. Mammographic density and findings on screening and diagnostic mammograms were classified according to the Breast Imaging-Reporting and Data System®. Cases were classified based on visible findings on prior screening mammograms as true (no findings), missed (obvious findings), minimal signs (minor/non-specific findings), or occult (no findings at diagnosis). Histopathologic tumor characteristics were extracted from the Cancer Registry of Norway. The Bonferroni correction was used to adjust for multiple testing; p

• Egeland, Nina Gran; Jonsdottir, Kristin; Aure, Miriam Ragle; Sahlberg, Kristine Kleivi; Kristensen, Vessela N. & Cronin-Fenton, Deirdre [Vis alle 10 forfattere av denne artikkelen] (2020). MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers. BMC Cancer. ISSN 1471-2407. 20. doi: 10.1186/s12885-020-06857-7. Fulltekst i vitenarkiv
• Tekpli, Xavier; Lien, Tonje Gulbrandsen; Røssevold, Andreas Hagen; Nebdal, Daniel J.H.; Borgen, Elin & Ohnstad, Hege Oma [Vis alle 19 forfattere av denne artikkelen] (2019). An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nature Communications. ISSN 2041-1723. 10:5499, s. 1–14. doi: 10.1038/s41467-019-13329-5. Fulltekst i vitenarkiv
• Hovda, Tone; Holen, åsne Sørlien; Lång, Kristina; Albertsen, Judy; Bjørndal, Hilde & Brandal, Siri Helene Bertelsen [Vis alle 10 forfattere av denne artikkelen] (2019). Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway. Radiology. ISSN 0033-8419. 294(2), s. 256–264. doi: 10.1148/radiol.2019191337. Vis sammendrag

  Background Screening that includes digital breast tomosynthesis (DBT) with two-dimensional (2D) synthetic mammography (SM) or standard 2D digital mammography (DM) results in detection of more breast cancers than does screening with DM alone. A decrease in interval breast cancer rates is anticipated but is not reported. Purpose To compare rates and characteristics of (a) interval breast cancer in women screened with DBT and SM versus those screened with DM alone and (b) screen-detected breast cancer at consecutive screenings with DM. Materials and Methods This prospective cohort study from BreastScreen Norway included women screened with DBT and SM (study group) or DM alone (control group) between February 2014 and December 2015 (baseline). All women, except nonattendees, women with breast cancer, and those who exceeded the upper age limit, were consecutively screened with DM after 2 years. Interval breast cancer, sensitivity, and specificity were estimated for women screened at baseline. Recall, screen-detected breast cancer, and positive predictive value were analyzed for consecutively screened women. A χ2 test, t test (P < .001 after Bonferroni correction indicated a significant difference), and binomial regression model were used to analyze differences across groups. Results A total of 92 404 women who underwent baseline screening (mean age, 59 years ± 6 [standard deviation]) were evaluated; 34 641 women in the study group (mean age, 59 years ± 6) were screened with DBT and SM and 57 763 women in the control group (mean age, 59 years ± 6) were screened with DM. A total of 26 474 women in the study group (mean age, 60 years ± 5) and 45 543 women in the control group (mean age, 60 years ± 5) were consecutively screened with DM. Rates of interval breast cancer were 2.0 per 1000 screened women in the study group and 1.5 per 1000 screened women in the control group (P = .12). No differences in histopathologic characteristics of interval breast cancer were observed. In the consecutive screening round, rates of screen-detected breast cancer were 3.9 per 1000 screened women (study group) and 5.6 per 1000 screened women (control group) (P = .001). Rates of histologic grade 1 invasive cancer were 0.5 per 1000 screened women (study group) and 1.3 per 1000 screened women (control group) (P = .001). Conclusion No differences in interval breast cancer rates or tumor characteristics were observed in women screened with DBT and SM compared with women screened with DM. Higher rates of low-grade screen-detected tumors were observed in the control group at consecutive screening.

• Madssen, Torfinn Støve; Cao, Maria Dung; Pladsen, Arne Valebjørg; Ottestad, Lars; Sahlberg, Kristine Kleivi & Bathen, Tone Frost [Vis alle 7 forfattere av denne artikkelen] (2019). Historical Biobanks in Breast Cancer Metabolomics — Challenges and Opportunities. Metabolites. ISSN 2218-1989. 9(11). doi: 10.3390/metabo9110278. Fulltekst i vitenarkiv
• Lindholm, Evita Maria; Aure, Miriam Ragle; Haugen, Mads Haugland; Sahlberg, Kristine Kleivi; Kristensen, Vessela N. & Nebdal, Daniel J.H. [Vis alle 9 forfattere av denne artikkelen] (2019). miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. Molecular Oncology. ISSN 1574-7891. 13(10), s. 2278–2296. doi: 10.1002/1878-0261.12561. Fulltekst i vitenarkiv
• Johansson, Henrik J.; Socciarelli, Fabio; Vacanti, Nathaniel M.; Haugen, Mads Haugland; Zhu, Yafeng & Siavelis, Ioannis [Vis alle 36 forfattere av denne artikkelen] (2019). Breast cancer quantitative proteome and proteogenomic landscape. Nature Communications. ISSN 2041-1723. 10:1600, s. 1–14. doi: 10.1038/s41467-019-09018-y. Fulltekst i vitenarkiv
• Lindholm, Evita Maria; Leivonen, Suvi-Katri; Due, Eldri Undlien; Nebdal, Daniel J.H.; Git, Anna & Caldas, Carlos [Vis alle 8 forfattere av denne artikkelen] (2019). miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth. MicroRNA. ISSN 2211-5366. 8(2), s. 155–165. doi: 10.2174/2211536608666181206124922.
• Tinholt, Mari; Garred, Øystein; Borgen, Elin; Beraki, Else; Schlichting, Ellen & Kristensen, Vessela N. [Vis alle 8 forfattere av denne artikkelen] (2018). Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 16(7), s. 1347–1356. doi: 10.1111/jth.14151.
• Fleischer, Thomas; Tekpli, Xavier; Mathelier, Anthony; Wang, Shixiong; Nebdal, Daniel J.H. & Dhakal, Hari Prasad [Vis alle 16 forfattere av denne artikkelen] (2017). DNA methylation at enhancers identifies distinct breast cancer lineages. Nature Communications. ISSN 2041-1723. 8(1379). doi: 10.1038/s41467-017-00510-x. Fulltekst i vitenarkiv
• Cui, Xue-Yan; Skretting, Grethe; Tinholt, Mari; Stavik, Benedicte; Dahm, Anders Erik A & Sahlberg, Kristine Kleivi [Vis alle 9 forfattere av denne artikkelen] (2017). A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. Thrombosis Research. ISSN 0049-3848. 157, s. 111–116. doi: 10.1016/j.thromres.2017.07.013.
• Jernström, Sandra Johanna; Hongisto, Vesa; Leivonen, Suvi-Katri; Due, Eldri Undlien; Tadele, Dagim Shiferaw & Edgren, Henrik [Vis alle 10 forfattere av denne artikkelen] (2017). Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer: Targets and Therapy. ISSN 1179-1314. 9, s. 185–198. doi: 10.2147/BCTT.S115600. Fulltekst i vitenarkiv
• Aure, Miriam Ragle; Vitelli, Valeria; Jernström, Sandra Johanna; Kumar, Surendra; Krohn, Marit & Due, Eldri Undlien [Vis alle 35 forfattere av denne artikkelen] (2017). Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Breast Cancer Research. ISSN 1465-5411. 19. doi: 10.1186/s13058-017-0812-y. Fulltekst i vitenarkiv Vis sammendrag

  Background Breast cancer is a heterogeneous disease at the clinical and molecular level. In this study we integrate classifications extracted from five different molecular levels in order to identify integrated subtypes. Methods Tumor tissue from 425 patients with primary breast cancer from the Oslo2 study was cut and blended, and divided into fractions for DNA, RNA and protein isolation and metabolomics, allowing the acquisition of representative and comparable molecular data. Patients were stratified into groups based on their tumor characteristics from five different molecular levels, using various clustering methods. Finally, all previously identified and newly determined subgroups were combined in a multilevel classification using a “cluster-of-clusters” approach with consensus clustering. Results Based on DNA copy number data, tumors were categorized into three groups according to the complex arm aberration index. mRNA expression profiles divided tumors into five molecular subgroups according to PAM50 subtyping, and clustering based on microRNA expression revealed four subgroups. Reverse-phase protein array data divided tumors into five subgroups. Hierarchical clustering of tumor metabolic profiles revealed three clusters. Combining DNA copy number and mRNA expression classified tumors into seven clusters based on pathway activity levels, and tumors were classified into ten subtypes using integrative clustering. The final consensus clustering that incorporated all aforementioned subtypes revealed six major groups. Five corresponded well with the mRNA subtypes, while a sixth group resulted from a split of the luminal A subtype; these tumors belonged to distinct microRNA clusters. Gain-of-function studies using MCF-7 cells showed that microRNAs differentially expressed between the luminal A clusters were important for cancer cell survival. These microRNAs were used to validate the split in luminal A tumors in four independent breast cancer cohorts. In two cohorts the microRNAs divided tumors into subgroups with significantly different outcomes, and in another a trend was observed. Conclusions The six integrated subtypes identified confirm the heterogeneity of breast cancer and show that finer subdivisions of subtypes are evident. Increasing knowledge of the heterogeneity of the luminal A subtype may add pivotal information to guide therapeutic choices, evidently bringing us closer to improved treatment for this largest subgroup of breast cancer.

• Sas-Chen, Aldema; Aure, Miriam Ragle; Leibovich, Limor; Carvalho, Silvia; Enuka, Yehoshua & Körner, Cindy [Vis alle 38 forfattere av denne artikkelen] (2016). LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Molecular Medicine. ISSN 1757-4676. 8(9), s. 1052–1064. doi: 10.15252/emmm.201606198. Fulltekst i vitenarkiv
• Tinholt, Mari; Sandset, Per Morten; Mowinckel, Marie-Christine; Garred, Øystein; Sahlberg, Kristine Kleivi & Kristensen, Vessela N. [Vis alle 10 forfattere av denne artikkelen] (2016). Determinants of acquired activated protein C resistance and D-dimer in breast cancer. Thrombosis Research. ISSN 0049-3848. 145, s. 78–83. doi: 10.1016/j.thromres.2016.08.003.
• Haukaas, Tonje Husby; Euceda, Leslie R.; Giskeødegård, Guro F.; Lamichhane, Santosh; Krohn, Marit & Jernström, Sandra Johanna [Vis alle 15 forfattere av denne artikkelen] (2016). Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer & Metabolism. ISSN 2049-3002. 4. doi: 10.1186/s40170-016-0152-x. Fulltekst i vitenarkiv
• Nunes-Xavier, Caroline Elisabeth; Flem Karlsen, Karine; Tekle, Christina; Pedersen, Cathrine; Øyjord, Tove Ragnhild & Hongisto, Vesa [Vis alle 10 forfattere av denne artikkelen] (2016). Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. OncoTarget. ISSN 1949-2553. 7(6), s. 6891–6901. doi: 10.18632/oncotarget.6902. Fulltekst i vitenarkiv
• Cui, Xue-Yan; Tinholt, Mari; Stavik, Benedicte; Dahm, Anders Erik A; Kanse, Sandip & Jin, Yang [Vis alle 11 forfattere av denne artikkelen] (2016). Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 14(2), s. 387–396. doi: 10.1111/jth.13206.
• Cui, Xueyan; Tinholt, Mari; Stavik, Benedicte; Dahm, Anders Erik A; Kanse, Sandip & Seidl, Sebastian [Vis alle 11 forfattere av denne artikkelen] (2015). Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer cell lines and tissues. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 13, s. 303–303.
• Tinholt, Mari; Vollan, Hans Kristian Moen; Sahlberg, Kristine Kleivi; Jernström, Sandra Johanna; Kaveh, Fatemeh & Lingjærde, Ole Christian [Vis alle 12 forfattere av denne artikkelen] (2015). Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. Breast Cancer Research. ISSN 1465-5411. 17(44), s. 1–15. doi: 10.1186/s13058-015-0548-5.
• Sahlberg, Kristine Kleivi; Bottai, Giulia; Naume, Bjørn; Burwinkel, Barbara; Calin, George A. & Børresen-Dale, Anne-Lise [Vis alle 7 forfattere av denne artikkelen] (2015). A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients. Clinical Cancer Research. ISSN 1078-0432. 21, s. 1207–1214. doi: 10.1158/1078-0432.CCR-14-2011.
• Aure, Miriam Ragle; Jernström, Sandra Johanna; Krohn, Marit; Vollan, Hans Kristian Moen; Due, Eldri Undlien & Rødland, Einar Andreas [Vis alle 14 forfattere av denne artikkelen] (2015). Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. Genome Medicine. ISSN 1756-994X. 7:21. doi: 10.1186/s13073-015-0135-5.
• Nygren, Marit; Tekle, Christina; Ingebrigtsen, Vibeke Anett; Mäkelä, Rami; Krohn, Marit & Aure, Miriam Ragle [Vis alle 17 forfattere av denne artikkelen] (2014). Identifyinig microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. British Journal of Cancer. ISSN 0007-0920. 15. doi: 10.1038/bjc.2014.113.
• Hongisto, Vesa; Aure, Miriam Ragle; Mäkelä, Rami & Sahlberg, Kristine Kleivi (2014). The HER2 ampicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description. Genomics Data. ISSN 2213-5960. 2, s. 249–253. doi: 10.1016/j.gdata.2014.06.025.
• Tinholt, Mari; Viken, Marte K; Dahm, Anders Erik A; Vollan, Hans Kristian Moen; Sahlberg, Kristine Kleivi & Garred, Øystein [Vis alle 16 forfattere av denne artikkelen] (2014). Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. BMC Cancer. ISSN 1471-2407. 14. doi: 10.1186/1471-2407-14-845.
• Leivonen, Suvi-Katri; Sahlberg, Kristine Kleivi; Mäkelä, Rami; Due, Eldri Undlien; Kallioniemi, Olli & Børresen-Dale, Anne-Lise [Vis alle 7 forfattere av denne artikkelen] (2014). High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Molecular Oncology. ISSN 1574-7891. 8(1), s. 93–104. doi: 10.1016/j.molonc.2013.10.001.
• Tahiri, Andliena; Leivonen, Suvi-Katri; Luders, Torben; Stenfeld, Israel; Aure, Miriam Ragle & Geisler, Jürgen [Vis alle 15 forfattere av denne artikkelen] (2014). Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis. ISSN 0143-3334. 35(1), s. 76–85. doi: 10.1093/carcin/bgt333.
• Sahlberg, Kristine Kleivi; Hongisto, Vesa; Edgren, Henrik; Makela, R; Hellstrøm, Kirsi & Due, Eldri Undlien [Vis alle 12 forfattere av denne artikkelen] (2013). The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Molecular Oncology. ISSN 1574-7891. 7(3), s. 392–401. doi: 10.1016/j.molonc.2012.10.012.
• Aure, Miriam Ragle; Steinfeld, I; Baumbusch, Lars Oliver; Liestøl, Knut; Lipson, Doron & Nyberg, Sandra Johanna [Vis alle 12 forfattere av denne artikkelen] (2013). Identifying In-Trans Process Associated Genes in Breast Cancer by Integrated Analysis of Copy Number and Expression Data. PLOS ONE. ISSN 1932-6203. 8(1). doi: 10.1371/journal.pone.0053014.
• Hongisto, Vesa; Jernström, Sandra Johanna; Fey, Vidal; Mpindi, John-Patrick; Sahlberg, Kristine Kleivi & Kallioniemi, Olli [Vis alle 7 forfattere av denne artikkelen] (2013). High-Throughput 3D Screening Reveals Differences in Drug Sensitivities between Culture Models of JIMT1 Breast Cancer Cells. PLOS ONE. ISSN 1932-6203. 8(10). doi: 10.1371/journal.pone.0077232.
• Aure, Miriam Ragle; Leivonen, Suvi-Katri; Fleischer, Thomas; Zhu, Qian; Overgaard, Jens & Alsner, Jan [Vis alle 19 forfattere av denne artikkelen] (2013). Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. Genome Biology. ISSN 1465-6906. doi: 10.1186/gb-2013-14-11-r126.
• Edgren, Henrik; Murumagi, Astrid; Kangaspeska, Sara; Nicorici, Daniel; Hongisto, Vesa & Kleivi, Kristine [Vis alle 11 forfattere av denne artikkelen] (2011). Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biology. ISSN 1465-6906. 12(1). doi: 10.1186/gb-2011-12-1-r6.
• Westbury, Charlotte B.; Kleivi Sahlberg, Kristine; Børresen-Dale, Anne-Lise ; Isacke, Clare M. & Yarnold, John R. (2011). Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients. Radiation Oncology. ISSN 1748-717X. 6. doi: 10.1186/1748-717X-6-42.
• Enerly, Espen; Steinfeld, Israel; Kleivi, Kristine; Leivonen, Suvi-Katri; Aure, Miriam Ragle & Russnes, Hege Elisabeth Giercksky [Vis alle 17 forfattere av denne artikkelen] (2011). miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors. PLOS ONE. ISSN 1932-6203. 6(2). doi: 10.1371/journal.pone.0016915.
• Rantala, Juha K.; Edgren, Henrik; Lehtinen, Laura; Wolf, Maija; Kleivi, Kristine & Vollan, Hans Kristian Moen [Vis alle 12 forfattere av denne artikkelen] (2010). Integrative Functional Genomics Analysis of Sustained Polyploidy Phenotypes in Breast Cancer Cells Identifies an Oncogenic Profile for GINS2. Neoplasia. ISSN 1522-8002. 12(11), s. 877–U50. doi: 10.1593/neo.10548.
• Muggerud, Aslaug; Hallett, Michael; Johnsen, Hilde; Kleivi, Kristine; Zhou, Wenjing & Tahmasebpoor, Simin [Vis alle 11 forfattere av denne artikkelen] (2010). Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Molecular Oncology. ISSN 1574-7891. 4(4), s. 357–368. doi: 10.1016/j.molonc.2010.06.007.
• Leivonen, SK; Makela, R; Ostling, P; Kohonen, P; Haapa-Paananen, S & Kleivi, Kristine [Vis alle 15 forfattere av denne artikkelen] (2009). Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. ISSN 0950-9232. 28(44), s. 3926–3936. doi: 10.1038/onc.2009.241.
• Muggerud, Aslaug Aamodt; Edgren, H; Wolf, M; Kleivi, Kristine; Dejeux, E & Tost, J [Vis alle 8 forfattere av denne artikkelen] (2009). Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. BMC Medical Genomics. ISSN 1755-8794. 2. doi: 10.1186/1755-8794-2-26.
• Kleivi, Kristine; Lind, Guro E; Diep, Chieu B; Meling, Gunn I; Brandal, Lin Thorstensen & Nesland, Jahn M [Vis alle 11 forfattere av denne artikkelen] (2007). Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Molecular Cancer. ISSN 1476-4598. 6. doi: 10.1186/1476-4598-6-2.
• Diep, C; Kleivi, Kristine; Ribeiro, FR; Teixeira, MR; Lingjærde, Ole Christian & Lothe, Ragnhild A (2006). The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes, Chromosomes and Cancer. ISSN 1045-2257. 45(1), s. 31–41.
• Kleivi, Kristine; Diep, Chiev B.; Pandis, Nikos; Heim, Sverre; Teixeira, Manuel R & Lothe, Ragnhild A (2005). TP53 mutations are associated with a paticular pattern of genomic imbalances in breast carcinomas. Journal of Pathology. ISSN 0022-3417. 207, s. 14–19. doi: 10.1002/path.1812.
• Kleivi, Kristine; Teixeira, Manuel R; Diep, Chiev B.; Eknæs, Mette; Jakobsen, Kjetill Sigurd & Hamelin, R. [Vis alle 7 forfattere av denne artikkelen] (2004). Genome signatures of colon carcinoma cell lines. Cancer Genetics and Cytogenetics. ISSN 0165-4608. 155, s. 119–131.

Se alle arbeider i Cristin

• Tinholt, Mari; Stavik, Benedicte; Sletten, Marit; Garred, Øystein; Tekpli, Xavier & Kristensen, Vessela N. [Vis alle 9 forfattere av denne artikkelen] (2019). Coagulation factor V is associated with immune response and tumor lymphocyte recruitment in breast cancer.
• Haukaas, Tonje Husby; Euceda, Leslie R.; Giskeødegård, Guro F.; Schlichting, Ellen; Kåresen, Rolf & Sauer, Torill [Vis alle 9 forfattere av denne artikkelen] (2016). Prediction of clinical prognostic markers in breast cancer using MR-based metabolic profiles.
• Haukaas, Tonje Husby; Euceda, Leslie R.; Giskeødegård, Guro F.; Lamichhane, Santosh; Krohn, Marit & Jernström, Sandra [Vis alle 15 forfattere av denne artikkelen] (2016). Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes.
• Haukaas, Tonje Husby; Euceda, Leslie R.; Giskeødegård, Guro F.; Schlichting, Ellen; Kåresen, Rolf & Sauer, Torill [Vis alle 9 forfattere av denne artikkelen] (2016). Prediction of clinical prognostic markers in breast cancer using MR-based metabolic profiles.
• Haukaas, Tonje Husby; Euceda, Leslie R.; Giskeødegård, Guro F.; Schlichting, Ellen; Kåresen, Rolf & Sauer, Torill [Vis alle 9 forfattere av denne artikkelen] (2016). Prediction of clinical prognostic markers in breast cancer using MR-based metabolic profiles.
• Haukaas, Tonje Husby; Euceda, Leslie R.; Giskeødegård, Guro F.; Krohn, Marit; Schlichting, Ellen & Kåresen, Rolf [Vis alle 10 forfattere av denne artikkelen] (2015). Combining ‘omics’; metabolic breast cancer clusters correlation with protein and gene expression subtypes.
• Haukaas, Tonje Husby; Euceda, Leslie R.; Giskeødegård, Guro F.; Krohn, Marit; Schlichting, Ellen & Kåresen, Rolf [Vis alle 10 forfattere av denne artikkelen] (2015). Combining ‘omics’; metabolic breast cancer clusters correlation with protein and gene expression subtypes.
• Haukaas, Tonje Husby; Euceda Wood, Leslie; Giskeødegård, Guro F.; Lamichhane, Santosh; Krohn, Marit & Schlichting, Ellen [Vis alle 14 forfattere av denne artikkelen] (2015). Interpreting the clinical relevance of metabolic subgroups in breast cancer in combination with gene- and protein- expression subtypes.
• Haukaas, Tonje Husby; Euceda Wood, Leslie; Giskeødegård, Guro F.; Krohn, Marit; Schlichting, Ellen & Kåresen, Rolf [Vis alle 10 forfattere av denne artikkelen] (2014). Metabolic subgrouping of breast cancer using HR MAS MRS and hierarchical cluster analysis; correlation with molecular subtypes.
• Aure, Miriam Ragle; Jernstrøm, Sandra; Krohn, Marit; Due, Eldri Undlien; consortium, OSBREAC & Mills, Gordon B. [Vis alle 11 forfattere av denne artikkelen] (2014). Integrative analysis reveals extensive association between microRNA expression and mRNA−protein translation. European Journal of Cancer. ISSN 0959-8049. 50, s. 79–79.
• Euceda Wood, Leslie; Haukaas, Tonje Husby; Giskeødegård, Guro F.; Krohn, Marit; Schlichting, Ellen & Kåresen, Rolf [Vis alle 10 forfattere av denne artikkelen] (2014). Metabolic subgrouping of breast cancer using HR MAS MRS and hierarchical cluster analysis; correlation with molecular subtypes.
• Hongisto, Vesa; Sahlberg, Kristine Kleivi; Edgren, H; Mäkelä, Rami; Due, Eldri Undlien & Vollan, Hans Kristian Moen [Vis alle 10 forfattere av denne artikkelen] (2012). The HER2 Amplicon Includes Several Genes Required for the Growth and Survival of HER2 Positive Breast Cancer Cells. European Journal of Cancer. ISSN 0959-8049. 48(Supp. 5), s. S82–S83.
• Sørlie, Therese; Muggerud, Aslaug; Hallett, Michael; Johnsen, Hilde; Sahlberg, Kristine Kleivi & Botling, Johan [Vis alle 8 forfattere av denne artikkelen] (2010). Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. European Journal of Cancer. ISSN 0959-8049. 8(5), s. 200–201.
• Enerly, Espen; Steinfeld, Israel; Sahlberg, Kristine Kleivi; Aure, Miriam Ragle; Leivonen, Suvi-Katri & Johnsen, Hilde [Vis alle 10 forfattere av denne artikkelen] (2010). Molecular characterization of breast cancer subtypes derived from joint analysis of high throughput miRNA and mRNA data. European Journal of Cancer. ISSN 0959-8049. 8(5), s. 164–164.
• Muggerud, Aslaug Aamodt; Sørlie, Therese; Kleivi, Kristine & Børresen-Dale, Anne-Lise (2009). Genetic and epigenetic alterations in breast tumour progression: The transition from in situ to invasive cancer. Unipub forlag. ISSN 978-82-8072-336-9.
• Kleivi, Kristine & Lothe, Ragnhild A (2006). Genome and transcriptome profiles of primary and advanced colorectal carcinomas. Unipub forlag. ISSN 82-8072-214-9.

Se alle arbeider i Cristin